Live

Watch: Fed Chair Jerome Powell speaks on interest rates, tariffs

Frankfurt - Delayed Quote EUR

Roivant Sciences Ltd. (87S.F)

8.73

-0.15

(-1.65%)

As of 3:29:02 PM GMT+2. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for 87S.F

Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.

Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board

Roivant Sciences price target lowered to $12 from $13 at BofA

Roivant Sciences price target lowered to $12 from $13 at BofA

News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts

News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Vivek Ramaswamy Open to Replacing JD Vance in Senate—if Offered

Vivek Ramaswamy Open to Replacing JD Vance in Senate—if Offered

IMU.AX Imugene Limited

0.0260

-7.14%

RARE Ultragenyx Pharmaceutical Inc.

33.59

-4.38%

IONS Ionis Pharmaceuticals, Inc.

27.64

-3.09%

ABSI Absci Corporation

2.1050

-5.82%

ALNY Alnylam Pharmaceuticals, Inc.

248.62

-5.16%

GNPX Genprex, Inc.

0.3518

-18.49%